Boer Willem, Van Tornout Mathias, Vander Laenen Margot, Engelen Kim, Meex Ingrid, Jorens Philippe
Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Medicine, Ziekenhuis Oost Limburg ZOL, Genk, Belgium.
Department of Anesthesiology and Intensive Care Medicine, AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium.
Kidney Int Rep. 2021 Aug 13;6(11):2775-2781. doi: 10.1016/j.ekir.2021.08.006. eCollection 2021 Nov.
Knowledge of effects of catheter port reversal (CathPR), when blood is withdrawn from the venous port and returned via the arterial port, often used in dysfunctional catheters in renal replacement therapy, is limited in the setting of citrate continuous veno-venous hemofiltration (CVVH).
In this open trial, post-filter ionized calcium (PfiCa), post-filter citrate concentration (PfCC), catheter recirculation, and solute clearance were measured before, during, and after 6 hours of CathPR, in well-functioning catheters. All other settings, including citrate settings, were left constant during the study.
Twenty-three patients were included. Mean PfiCa before CathPR of 0.36 mmol/L (SD 0.06) decreased to 0.31 (0.04) after 2 hours ( = 0.002), 0.31 (0.04) ( = 0.002) at 4 hours, and 0.31 (0.04) at 6 hours ( = 0.001). Return to normal increased mean PfiCa to 0.34 (0.06) ( = 0.006). Mean PfCC rose from 592 mg/L (SD 164) before CathPR to 649 mg/L (190) after 2 hours ( = 0.045), to 696 mg/L (192) after 4 hours ( < 0.001), and to 657 mg/L (214) after 6 hours ( = 0.018). Return to normal decreased mean PfCC to 598 mg/L (184) ( = 0.024). Mean recirculation increased during CathPR (from 4.3% [0-8.7] before to 13.8% [9.7-22.2], < 0.001). Urea, potassium, and creatinine clearances dropped significantly, but calcium clearance was unaffected.
CathPR caused a significant decrease in PfiCA and increase in PfCC. Calcium handling differs from other solutes because of increases caused in citrate concentration and subsequent effects on calcium chelation. In citrate CVVH, CathPR in dysfunctional catheters should be limited in time, with intensive follow-up. Trial registration: ClinicalTrials.gov: NCT024600416. Registered 9 November 2015.
在枸橼酸盐持续静脉-静脉血液滤过(CVVH)中,对于导管端口反转(CathPR)(即从静脉端口抽血并通过动脉端口回输,常用于肾脏替代治疗中功能失调的导管)的影响了解有限。
在这项开放性试验中,对功能良好的导管,在CathPR进行6小时之前、期间和之后测量滤器后离子钙(PfiCa)、滤器后枸橼酸盐浓度(PfCC)、导管再循环和溶质清除率。在研究期间,所有其他设置,包括枸橼酸盐设置,均保持不变。
纳入23例患者。CathPR前平均PfiCa为0.36 mmol/L(标准差0.06),2小时后降至0.31(0.04)(P = 0.002),4小时时为0.31(0.04)(P = 0.002),6小时时为0.31(0.04)(P = 0.001)。恢复正常后平均PfiCa升至0.34(0.06)(P = 0.006)。平均PfCC从CathPR前的592 mg/L(标准差164)在2小时后升至649 mg/L(190)(P = 0.045),4小时后升至696 mg/L(192)(P < 0.001),6小时后升至657 mg/L(214)(P = 0.018)。恢复正常后平均PfCC降至598 mg/L(184)(P = 0.024)。CathPR期间平均再循环增加(从之前的4.3%[0 - 8.7]升至13.8%[9.7 - 22.2],P < 0.001)。尿素、钾和肌酐清除率显著下降,但钙清除率未受影响。
CathPR导致PfiCa显著降低和PfCC升高。由于枸橼酸盐浓度增加及其对钙螯合的后续影响,钙的处理与其他溶质不同。在枸橼酸盐CVVH中,功能失调导管的CathPR应限制时间,并进行密切随访。试验注册:ClinicalTrials.gov:NCT024600416。2015年11月9日注册。